Skip to main content
BiotoxtechCo.,Ltd. logo

BiotoxtechCo.,Ltd. — Investor Relations & Filings

Ticker · 086040 ISIN · KR7086040003 KO Professional, scientific and technical activities
Open in API
Filings indexed 172 across all filing types
Latest filing 2025-03-13 AGM Information
Country KR South Korea
Listing KO 086040

About BiotoxtechCo.,Ltd.

http://eng.biotoxtech.com/

Biotoxtech Co., Ltd. is a non-clinical Contract Research Organization (CRO) that provides safety and efficacy evaluation services. The company offers a comprehensive suite of GLP-compliant studies, including general toxicity, carcinogenicity, reproductive and developmental toxicity, genotoxicity, immunotoxicity, and safety pharmacology. It also conducts efficacy evaluations and provides analytical research services such as pharmacokinetics (PK/TK/ADME) and bioanalysis. Biotoxtech serves a diverse clientele developing pharmaceuticals, biomedicines, cell and gene therapies, medical devices, chemicals, agrochemicals, cosmetics, and health functional foods.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal notification filed by Biotoxtech regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling conflict and provides details on the meeting date and notice date. As this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or voting results, it falls under the general regulatory filing category.
2025-03-13 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Biotoxtech Co., Ltd. It contains the meeting agenda, including the approval of financial statements, election of directors, and remuneration limits. While it includes financial tables, these are provided as part of the 'Management Reference' (경영참고사항) section required for shareholder meetings under Korean law. This document is a proxy statement/notice for an upcoming meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement) used to request shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting date, agenda items, and proxy voting procedures. This fits the definition of a Proxy Solicitation & Information Statement.
2025-03-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special related parties, including specific transaction dates, methods (e.g., open market purchases), and the purpose of holding (influence on management). This fits the definition of a Major Shareholding Notification.
2025-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Biotoxtech) announcing a significant change (over 30%) in revenue or profit structure. This is a standard periodic financial disclosure required by the Korea Exchange (KRX) for listed companies to report preliminary financial results before the final audit report is finalized. Since it provides key financial highlights and performance metrics for the fiscal year, it fits the definition of an Earnings Release (ER). FY 2024
2025-02-27 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a 'Trust Contract Termination Result Report' (신탁계약해지결과보고서) filed by Biotoxtech Co., Ltd. with the Financial Supervisory Service (FSS). It details the termination of a stock repurchase trust contract, the acquisition status of treasury shares through that trust, and the final status of treasury shares held after the termination. This falls under the category of 'Transaction in Own Shares' (POS) as it reports the conclusion of a share buyback program and the resulting change in treasury share holdings.
2025-02-03 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.